Can-Fite BioPharma Ltd.CANFNYSE
LOADING
|||
Year-over-year revenue growth rate
| Period | Value |
|---|---|
| Q2 2025 | 0.00% |
| Q1 2025 | -43.58% |
| Q4 2024 | 0.00% |
| Q3 2024 | 13.29% |
| Q2 2024 | 0.00% |
| Q1 2024 | 1.94% |
| Q4 2023 | -20.92% |
| Q3 2023 | 0.00% |
| Q2 2023 | 0.00% |
| Q1 2023 | -0.51% |
| Q4 2022 | -3.43% |
| Q3 2022 | 0.00% |
| Q2 2022 | -0.49% |
| Q1 2022 | 0.49% |
| Q4 2021 | -18.73% |
| Q3 2021 | 0.40% |
| Q2 2021 | 68.92% |
| Q1 2021 | -1.33% |
| Q4 2020 | -28.91% |
| Q3 2020 | 3.43% |
| Q2 2020 | 3.03% |
| Q1 2020 | 3.13% |
| Q4 2019 | -83.33% |
| Q3 2019 | 196.14% |
| Q2 2019 | 30.10% |
| Q1 2019 | 3.46% |
| Q4 2018 | -89.01% |
| Q3 2018 | 873.70% |
| Q2 2018 | -57.28% |
| Q1 2018 | 501.77% |
| Q4 2017 | -82.11% |
| Q3 2017 | 639.10% |
| Q2 2017 | 8.17% |
| Q1 2017 | 4264.95% |
| Q4 2016 | -102.92% |
| Q3 2016 | 10.80% |
| Q2 2016 | -3.91% |
| Q1 2016 | 109.44% |
| Q4 2015 | -59.04% |
| Q3 2015 | -7.96% |